Objective To describe the incidence of mechanical prosthetic heart valves (MPHV) in pregnancy in the UK; rates of maternal and fetal complications in this group of women, and whether these vary with the anticoagulation used during pregnancy.
Introduction
Women with mechanical prosthetic heart valves (MPHV) require lifelong anticoagulation to prevent valve thrombosis.
Pregnancy is thrombogenic, and so represents a time of significant clinical risk. It is believed that increasing numbers of women with MPHVs are embarking on pregnancy, 1 but optimal clinical management is hampered by a lack of good quality data on maternal mortality and rates of complications.
Three anticoagulant regimens are commonly used in pregnancy: warfarin throughout; low-molecular-weight heparin (LMWH) throughout; or LMWH in the first trimester, then warfarin until the mid-third trimester, converting back to LMWH or unfractionated heparin before delivery. Warfarin is thought to have the lowest risk of maternal complications 2 but is associated with higher rates of fetal complications and demise. 3, 4 LMWH is safe for the fetus, but doubts have been expressed about its efficacy in preventing maternal complications. 5, 6 European Society for Cardiology guidelines have called for more research to identify the best treatment for pregnant women. 7 Various expert groups have suggested that women themselves should make an 'informed choice' about which regimen to use but currently there is very little evidence to aid them in this choice.
The aims of this study were 1 to ascertain how many women with MPHVs become pregnant each year in the UK 2 to report the incidence of fetal and maternal complications in women with MPHVs in pregnancy 3 to describe the incidence of complications associated with the different anticoagulation regimens used in contemporary UK practice.
Methods

Research design
This prospective descriptive population-based study used the United Kingdom Obstetric Surveillance System (UKOSS) data collection system to identify all women in the UK with MPHVs in pregnancy. 8 
Case definition
A case was defined as any woman in the UK, with an artificial mechanical prosthetic heart valve, who became pregnant in a 2-year period between 1 February 2013 and 31 January 2015, irrespective of the pregnancy outcome. This included any woman in whom one or more heart valves had been replaced with an artificial mechanical prosthetic heart valve. Women with a bioprosthetic valve or homograft were excluded.
Data collection
Cases were identified from a monthly mailing of UKOSS notification cards to a nominated reporting clinician in each of the 210 UK hospitals with a consultant-led maternity unit. They were asked to return all cards, including those with 'nil to report'. When a card was returned indicating that there had been a pregnancy in a woman with a prosthetic valve, the reporting clinician was sent a data collection form. The form gathered detailed information about the woman including the type and position of valve, anticoagulant regimen, and maternal and fetal outcomes. Cases were allocated UKOSS identification numbers and all data were anonymous. Once received, duplicate cases were excluded by comparison of key clinical information. The data were double entered into a customised database by two individuals and the data were compared to minimise data entry errors. Case details were reviewed against the case definition and all cases that did not meet the inclusion criteria were excluded. Reminders were sent if forms were not returned or were incomplete. At the close of the data collection period, contact was made with specialist centres to check that case ascertainment was complete.
Statistical analysis
Since women with MPHVs would not be cared for in any setting other than a consultant-led maternity unit, data on cases were obtained from these units. The total number of maternities in the UK over the 2 years of the study was used as the denominator when calculating the incidence. This study therefore covers the entire birth cohort within the UK. Incidence was calculated with 95% confidence intervals.
Maternal and neonatal outcomes were compared in prespecified subgroups according to the anticoagulant regimen used. Anticoagulant regimens were categorised as 'Warfarin throughout', 'LMWH throughout' and 'First-trimester LMWH with subsequent warfarin' or 'Other'. Reporting clinicians were asked to select the regimen that best described the woman's anticoagulation management, and data were also collected on the anticoagulant being used at 10 and 20 weeks of gestation.
A poor maternal outcome was defined as maternal death or serious morbidity-admission to intensive care for more than one day; valve thrombosis or valve dysfunction resulting in heart failure; cerebrovascular accident; or bleeding complications requiring transfusion or return to theatre (primary postpartum haemorrhage, secondary postpartum haemorrhage, intra-abdominal bleeding, vaginal haematoma, wound haematoma). A poor fetal outcome was defined as any pregnancy loss (miscarriage or termination of pregnancy), stillbirth, neonatal death, fetal abnormality, Apgar score of < 7 at 5 minutes, or admission to the neonatal unit.
Maternal death was defined as death during pregnancy or up to 42 days after delivery. Miscarriage was the loss of pregnancy up to 24 weeks of gestation. Stillbirth was a baby born following an intrauterine fetal death after 24 weeks 0 days gestation. Preterm birth was defined as delivery before 37 weeks gestation.
Ethics committee approval
The UKOSS general methodology (04/MRE02/45) was approved by the London Multicentre Research Ethics Committee. This study was approved by the NRES Committee Yorkshire & Humber-Sheffield (study reference 13/YH/ 0048: 7 February 2013).
Results
All 210 hospitals with consultant-led maternity units in the UK participated in the study.
Eighty-three cases were reported, and 75 forms were returned. There were eight duplicates and nine women did not meet the case definition. No additional cases were identified through sources other than UKOSS. Hence there were 58 women with confirmed MPHVs in pregnancy, in an estimated 1 555 000 maternities, giving an overall estimated incidence of 3.7 (95% CI 2.7-4.7) per 100 000 maternities. Table 1 shows the demographic characteristics of the women.
One of the 58 women in the study had her prosthetic valve implanted during pregnancy (second trimester). Of the 57 women who had MPHVs before pregnancy, 33 (58%) presented before 7 weeks of gestation. Five women miscarried (three in the first trimester and two in the second trimester), four women terminated their pregnancies and two women died undelivered. The number of women who had presented for care and had ongoing pregnancies therefore changes across gestation with 33 women before 7 weeks of gestation; 43 women at 10 weeks; 47 women at 20 weeks and 47 women reaching the third trimester (> 24 weeks of gestation).
Of the 57 women who had a prosthetic valve in situ before becoming pregnant, 13 (23%) had not been reviewed by a cardiologist in the year preceding their pregnancy (one woman had a prosthetic valve inserted during pregnancy). Eleven women (19%) were not referred either to tertiary care or to a specialist obstetric-cardiology service during their pregnancy.
Twenty-nine women (51%) had prepregnancy counselling; 28 women (49%) either did not, or there was no evidence of it recorded. One woman underwent a valve replacement at 20 weeks of gestation following an unexpected aortic dissection, hence prepregnancy counselling was impossible. The women who had received prepregnancy counselling did not present earlier in gestation (median 6 weeks, range 4-16 weeks), than those who had not (median 7 weeks, range 4-24 weeks) (Wilcoxon P = 0.29).
Haematological management
Of the 33 women who presented at less than 7 weeks of gestation, three (9%) were already using LMWH prepregnancy, and 21 (64%) converted to LMWH before 7 weeks of gestation; two of these women (6%) used warfarin throughout pregnancy; one (3%) elected to have a termination and therefore did not convert to LMWH. In four women (12%), the timing of conversion to LMWH was not known and in two women (6%) it occurred between 7 and 8 weeks of gestation.
The most common anticoagulant regimen was LMWH throughout pregnancy, which 71% of women used (Table 2) .
At 10 weeks of gestation, 25 of the 30 (83%) women using LMWH required a dose in excess of that recommended in the British National Formulary (BNF). 9 At 20 weeks of gestation 25 of the 28 women (89%) required a higher dose. Data on the monitoring regimen were provided for 32 women. There was variation in the frequency of monitoring anti-Xa levels, varying from not at all to weekly. Post-dose anti-Xa levels were taken between 0 and 5 hours (median 3 hours). In 15 of 32 (47%) women only post-dose anti-Xa levels were checked (not pre-dose). The incidence of maternal complications was similar in the women who only had post-dose anti-Xa levels checked (47%) compared with those who had both pre-and post-dose levels (52%).
There was wide variation in target ranges documented, but the median target ranges stated were pre-dose 0.3-1 U/ ml and post-dose 0.9-1.2U /ml. For 11 women, the reported target ranges were inappropriate for pregnancy 7 with the lower end of the pre-dose target range being given as 'detectable' for three women, and the upper end of the post-dose target range being given as 2.5 U/ml for eight women.
The median number of times anti-Xa levels were monitored was 10 (range 0-75). In the 40 women where it could be assessed, doses of LMWH were changed after monitoring on 126 of 591 occasions (21% of the time). Women who experienced thrombotic complications (n = 8), were more likely to be using an inappropriate dose and need a dose change (50% of the time) than those who did not have thrombotic complications (17% of the time) (chisquare P < 0.001). There was a non-significant trend for women with thrombotic complications to have less frequent monitoring (median eight compared with median ten in women without thrombotic complications).
Of the 24 women who remained on the same preparation of LMWH throughout pregnancy only 7 did not require a dose increase between 10 and 20 weeks of gestation. Sixteen women required a 12-100% increase in dose (Unable to assess one woman).
Poor compliance was reported for 11 women, 7 (64%) of whom had a poor maternal outcome. Of the 47 women with good compliance, 22 (47%) had a poor maternal outcome (chi-square 0.5 > P > 0.1). The proportion of thrombotic complications was similar in women with poor reported compliance (50%), and no reported compliance problems (42%).
Of the 47 women who reached the third trimester, information was available about the timing of reintroduction of warfarin postnatally for 39. The median time for recommencement of warfarin was 2 days postnatally (range 0-35). For women with bleeding complications the median was 5 days (n = 16, range 1-35), and for those who did not experience bleeding complications it was 2 days (n = 23, range 0-8).
Obstetric management
There were 47 women who reached the third trimester of pregnancy (> 24 weeks 0 days gestation). One was lost to follow up and no data are available about the management of delivery or neonatal outcome. There was a care plan for delivery in the notes of 40 (85%) women, and 39 of these included the management of anticoagulation.
Twenty-one women (45%) had a vaginal delivery, with 25 (53%) having a lower-segment caesarean section (LSCS) (one was not known) ( Table 3 ). Only one LSCS was performed in labour. There was no difference in the proportion of nulliparous (45%) or parous (44%) women who delivered vaginally.
Of the 25 LSCS, five were performed for fetal compromise, 13 for maternal compromise, three in view of previous LSCS, one for maternal request, one for failed induction, one for failure to progress in labour and one indication not known.
Maternal outcomes
There were five deaths (9%) among this group of 58 women with an MPHV in pregnancy. Their ages ranged from 24 to 38 years; two were nulliparous; three were White British and two were African. Their prosthetic valves had been implanted between 1 and 22 years before the pregnancy: two were in the aortic position and three in the mitral position. Four women had prepregnancy counselling. All women were using warfarin before pregnancy, but all changed to LMWH during pregnancy. Two women with valve thrombosis died in the first half of pregnancy; two women died immediately postpregnancy from valve dysfunction/ cardiac failure; one women died from a cerebrovascular accident.
In addition to the women who died, 24 women (41%) had serious maternal morbidity (Table 3 ). Postpartum bleeding complications that necessitated return to theatre or transfusion were experienced by 17 (29%) women. Of the 25 women delivered by LSCS, ten (40%) needed to return to theatre due to bleeding complications; seven (33%) of the 21 women who delivered vaginally had haemorrhagic complications (P > 0.5 chi-square test).
Of the 28 women with a prosthetic mitral/ systemic atrioventricular valve alone, 16 (57%) had serious maternal morbidity or mortality; of the 26 women with a prosthetic aortic valve alone the figure was 10 (39%), (0.5 > P > 0.1 chi-square test). Of the four women with both a prosthetic mitral and aortic valve, three (75%) had serious maternal morbidity or mortality. In the surviving women, all five valve thromboses occurred in women with prosthetic mitral valves; of the four women who had cerebrovascular accidents, three had prosthetic aortic valves and one had a prosthetic mitral valve.
The proportion who smoked was 22%, almost double that of the UK pregnant population. 10 . Smoking status was not related to poor maternal outcome (0.5 > P > 0.1 chisquare test).
Neonatal outcome
There was poor fetal outcome in 27 (47%, 95% CI 34-59%) of the 58 pregnancies, and in 16 (35%, 95% CI 21-49) of those reaching the third trimester (Table 3) . If terminations of pregnancy were excluded from the analysis, 43% of pregnancies had a poor fetal outcome. Of the eleven babies born before 37 weeks of gestation, three were due to spontaneous preterm labour, the other eight were delivered electively (five due to fetal compromise and three for maternal reasons).
There were two fetal anomalies; one fetal warfarin syndrome in a woman who used warfarin throughout her pregnancy and one inherited genetic condition compatible with long-term survival (unrelated to cardiac condition or anticoagulation). In addition, two women had red cell antibodies rendering the fetus at risk of alloimmunisation.
Maternal and fetal outcomes associated with the different anticoagulation regimens
Overall, only 16 women (28%) had good maternal and fetal outcomes. In women using LMWH throughout pregnancy only 8 of the 41 women (20%) had good maternal and fetal outcomes, whereas in the women using LMWH in the first trimester and warfarin subsequently this was the case for five of the nine women (56%) ( Table 4) .
Discussion
Main findings
This study estimated the incidence of MPHVs to be 3.7 per 100 000 maternities in the UK. It includes the largest cohort of women with MPHVs managed with LMWH throughout pregnancy reported to date. It demonstrates a high rate of maternal death, and serious maternal and fetal morbidity.
Strengths and limitations
The data collection methodology used provides an unbiased cohort and is the only prospective, population-based (national) study of pregnancies with MPHVs in situ. Other published cohorts relate to self-selecting centres, 6, [11] [12] [13] [14] [15] particular treatment regimens, 2, 15, 16 valves in a particular position, 15, 17 or are retrospective population studies of birth registry data. 1, 18 The limitations of this study are that some data were incomplete as the care of many women was shared between different disciplines and, frequently between different hospitals. In addition to the 58 women in the study, a further 8 notifications were received but the data collection form was not returned. As the study was prospective, the implication of the data collection process on the practice of the centres involved is unknown. To preserve anonymity of women some details could not be reported as the woman would become identifiable.
In this national study over a 2-year period, the number of women remained small, so limiting the study power to detect as statistically significant, what might be clinically important differences between subgroups. This was particularly true when considering outcomes with different anticoagulant regimens. Small numbers also limited the ability to investigate confounders such as underlying cardiac diagnosis or functional status.
Interpretation
Incidence of MPHVs in pregnancy in the UK (2013-15) During the study period 3.7 per 100 000 maternities (95% CI 2.7-4.7 per 100 000) occurred in women with MPHVs, higher than in the only other study to estimate incidence 18 (1.8/100 000 maternities 95% CI 1.0-2.5 per 100 000 in New South Wales, Australia 2000/11). This could represent differences in populations; an increase in the number of women with MPHVs embarking on pregnancy; 1 or better case ascertainment.
Incidence of fetal and maternal complications in women with MPHVs in pregnancy There were high rates of maternal mortality (9%) and serious maternal morbidity (41%): 16% of women sustained valve thrombosis or dysfunction; 9% suffered cerebrovascular accident; 29% had obstetric haemorrhage. These Table 4 . Overall maternal and fetal outcomes related to anticoagulation regimen in pregnancy (and expressed as a percentage of the number of women using each regimen)
Poor maternal outcome
Poor maternal outcome
Good maternal outcome
Good maternal outcome figures are higher than those reported in a recent systematic review (maternal mortality 1.8%; obstetric haemorrhage 11.1%; thromboembolic event 13.9%) 19 or in the largest single series to date (ROPAC Registry) (maternal mortality 1.4%, thrombotic complications 6.1%, heart failure 7.5%, haemorrhagic complications 23.1%). 20 Our study was a prospective national cohort study and therefore less likely to be subject to reporting bias. Alternatively, it could reflect a real increase in the rate of maternal complications with the anticoagulation regimens used. The majority of women in our study were using LMWH, whereas those in studies included in the systematic review 19 and the ROPAC registry 20 mainly used warfarin, either throughout, or during the second and third trimesters of pregnancy.
The rate of haemorrhagic complications (29%), was similar to that reported by Abildgaard (33%). 16 In common with this study, the complications were predominantly due to secondary haemorrhage (wound haematoma, secondary postpartum haemorrhage and intra-abdominal bleeding). Although secondary haemorrhage is a recognised postoperative complication occurring when warfarin is restarted, 21 in our study it did not appear to be due to early rewarfarinisation. The appropriate anticoagulation regimen, in the immediate postpartum period when circulating volume is changing rapidly, is still unknown.
There was a suggestion of worse maternal outcomes in women with a prosthetic mitral/ systemic atrioventricular valve (57%), compared with an aortic valve (39%), although this was not statistically significant. Women with two MPHVs had the worst outcomes (75%). In this cohort, where valve thrombosis complicated pregnancy it only occurred in association with prosthetic mitral valves. The ROPAC registry also suggested more valve thromboses in the women with prosthetic mitral valves (mitral 4.4%, aortic 2.6%). 20 Few published series detail neonatal outcomes, yet this appears to be important to women and influences their choice of anticoagulation regimen. This study demonstrates a high rate of fetal morbidity and mortality, with a poor fetal outcome in 47% of the cohort, and 35% of those reaching the third trimester, higher than other reported series. 18, 20 Incidence of fetal and maternal complications with the different anticoagulation regimens used This study has described outcomes with different treatment regimens, although statistically significant differences cannot be demonstrated due to low numbers of women using regimens other than LMWH throughout pregnancy (Table 4) causing limited study power.
LMWH throughout pregnancy was used by 71% of women and appears to be the preferred treatment in the UK. Despite doubts having been expressed about its efficacy in preventing maternal complications, it is neither teratogenic nor fetotoxic and therefore may be chosen by women prioritising the health of their baby. Although some previous studies report on a larger number of women with prosthetic valves in pregnancy, 1, 15, 20 our study includes the largest number of women with prosthetic valves managed with LMWH throughout pregnancy.
By 10 weeks of gestation, 83% of women needed doses of LMWH higher than recommended in the British National Formulary. 9 Further dose escalation was needed between 10 and 20 weeks gestation. Cases of valve thrombosis associated with subtherapeutic Anti-Xa levels in early pregnancy have been described. 16, 20 Our data suggest that more appropriate starting doses would be 2.5 mg/kg for enoxaparin, 250 iu/kg for dalteparin and 250 iu/kg for tinzaparin to ensure minimal delay in reaching the target range.
Thrombotic complications were associated with a greater need for dose changes following monitoring of Anti-Xa levels. Several authors have described thrombotic complications being more likely in association with subtherapeutic Anti-Xa levels, either due to noncompliance or subtherapeutic dosing. 6, 16, [22] [23] [24] [25] [26] Although the importance of predose (trough) Anti-Xa levels has been emphasised by some authors, 27 ,28 monitoring of trough Anti Xa levels has not been incorporated into specialist society guidelines. 7, 29, 30 There is a lack of consistency within the guidelines on frequency of monitoring, target ranges and the timing of post-dose (peak) Anti-Xa levels. 7, 29, 30 It is therefore unsurprising that there was marked variation in the monitoring of LMWH treatment in our study. Outcomes may appear to be better in the women treated with warfarin, but this may be due to there being more consistent guidance regarding its monitoring and target ranges for MPHVs.
Conclusion
This prospective national study reflects current UK practice because it included all women with an MPHV, irrespective of gestation. It has shown that this rare condition is associated with a high risk of poor fetal and maternal outcome. Despite a lack of evidence to guide practice, the majority of women with prosthetic valves in the UK are using LMWH throughout pregnancy. There is wide variation in dosing and monitoring regimens, and the recommended weightbased starting doses appear to be insufficient. The poor outcomes found in this group of women may relate to adequacy of their anticoagulation or may relate to the efficacy of LMWH itself. The information from this study may lead women and clinicians to re-evaluate this choice.
Women with MPHVs, and their clinicians need to appreciate the significant risks involved in pregnancy and the need for specialist care to concentrate experience of this rare condition.
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